Avandia (generic: rosiglitazone), a medication used in the treatment of type II diabetes, may be responsible for various severe, life-threatening complications including heart attacks and strokes.
November 16, 2012 — 38 states will split a $90 million settlement with GlaxoSmithKline over marketing of Avandia. Click here to read more.
July 2012 –– GlaxoSmithKline will pay $3 billion to the federal U.S. government for minimizing links between Avandia and heart attack, stroke, and death.
Manufactured by GlaxoSmithKline (GSK), Avandia was first approved by the U.S. Food and Drug Administration (FDA) in 1999 to treat the symptoms of type II diabetes. However, reports of significant adverse health effects began surfacing in 2007 when a substantial increase in heart attacks and strokes became associated with Avandia side effects.
Recent studies suggest that the continual use of Avandia may be linked to severe, life-threatening cardiovascular problems including heart attack and stroke. As a result of these findings, GSK was included in a two year congressional hearing that acknowledged the company knew about the potential side effects of Avandia. GSK demonstrated a reckless disregard for public safety when they pressured doctors into retracting the warnings associated with Avandia side effects.